The Medicines Co. (MDCO)

26.54
0.60 2.20
NASDAQ : Health Technology
Prev Close 27.14
Open 27.22
Day Low/High 26.41 / 27.34
52 Wk Low/High 16.69 / 41.57
Volume 435.55K
Avg Volume 1.31M
Exchange NASDAQ
Shares Outstanding 73.86M
Market Cap 2.00B
EPS -4.00
P/E Ratio N/A
Div & Yield N.A. (N.A)
The Medicines Company To Present Data From Its Investigational Anesthetic MDCO-700 At The ANESTHESIOLOGY® 2016 Annual Meeting And The ISAP 25th Annual Meeting

The Medicines Company To Present Data From Its Investigational Anesthetic MDCO-700 At The ANESTHESIOLOGY® 2016 Annual Meeting And The ISAP 25th Annual Meeting

The Medicines Company (NASDAQ:MDCO) today announced that five abstracts with data from its investigational anesthetic MDCO-700 (formerly, ABP-700) development program will be presented at ANESTHESIOLOGY® 2016,...

Why Medicines Co. (MDCO) Stock is Falling Today

Why Medicines Co. (MDCO) Stock is Falling Today

Medicines Co. (MDCO) stock is under pressure today because its drug development partner Alnylam Pharmaceuticals (ALNY) ended testing on one of its gene-silencing treatments.

The Medicines Company Provides Progress Update On Ongoing ORION-1 Study Of PCSK9si

The Medicines Company Provides Progress Update On Ongoing ORION-1 Study Of PCSK9si

The Medicines Company (NASDAQ:MDCO) today provided a progress update on the ongoing ORION-1 study of PCSK9si, its investigational first-in-class PCSK9 synthesis inhibitor.

Notable Wednesday Option Activity: MDCO, PEIX, BEAT

Notable Wednesday Option Activity: MDCO, PEIX, BEAT

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Medicines Co , where a total volume of 4,663 contracts has been traded thus far today, a contract volume which is representative of approximately 466,300 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 57.9% of MDCO's average daily trading volume over the past month, of 805,825 shares.

The Medicines Company Awarded Up To $132 Million To Develop Portfolio Of New Antibiotics Targeting Drug-Resistant Infections Under Strategic Partnership With BARDA

The Medicines Company Awarded Up To $132 Million To Develop Portfolio Of New Antibiotics Targeting Drug-Resistant Infections Under Strategic Partnership With BARDA

The Medicines Company (NASDAQ:MDCO) today announced that it has entered into a new strategic partnership with the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant...

CORRECTING and REPLACING The Medicines Company Provides Update on Dyslipidemia Programs

CORRECTING and REPLACING The Medicines Company Provides Update on Dyslipidemia Programs

The third paragraph of release dated August 30, 2016, should read: The Company has completed enrollment of the planned 120 patients and expects that results from the MILANO-PILOT study will be presented by its principal...

The Medicines Company Reports Second-Quarter 2016 Business And Financial Results

The Medicines Company Reports Second-Quarter 2016 Business And Financial Results

The Medicines Company (NASDAQ:MDCO) today announced its business and financial results for the second quarter ended June 30, 2016.

The Medicines Company To Announce Second Quarter Financial Results On July 27, 2016

The Medicines Company To Announce Second Quarter Financial Results On July 27, 2016

The Medicines Company (NASDAQ:MDCO) has scheduled its quarterly conference call for July 27, 2016 at 8:30 a.

Federal Circuit Rules For The Medicines Company In Angiomax® (bivalirudin) Patent Litigation

Federal Circuit Rules For The Medicines Company In Angiomax® (bivalirudin) Patent Litigation

The Medicines Company announced that the U.S.

Barbarian At The Gate: Medicines (MDCO)

Barbarian At The Gate: Medicines (MDCO)

Trade-Ideas LLC identified Medicines (MDCO) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

Medicines (MDCO) Flagged As Strong On High Volume

Medicines (MDCO) Flagged As Strong On High Volume

Trade-Ideas LLC identified Medicines (MDCO) as a strong on high relative volume candidate

The Medicines Company Announces Positive Top- Line Results For Phase 3 TANGO 1 Clinical Trial Of CARBAVANCE®

The Medicines Company Announces Positive Top- Line Results For Phase 3 TANGO 1 Clinical Trial Of CARBAVANCE®

The Medicines Company (NASDAQ:MDCO) today announced that its investigational antibiotic, CARBAVANCE ® (meropenem-vaborbactam), met both FDA and EMA pre-specified primary endpoints in the Phase 3 TANGO 1 clinical trial...

The Medicines Company Completes Divestiture Of Its Non-Core Cardiovascular Assets To Chiesi

The Medicines Company Completes Divestiture Of Its Non-Core Cardiovascular Assets To Chiesi

The Medicines Company (NASDAQ:MDCO) today announced the completion of the previously-disclosed divestiture of its non-core cardiovascular assets, Cleviprex® (clevidipine) injectable emulsion, Kengreal® (cangrelor)...

Insiders Are Scooping Up Shares of These 5 Stocks

Insiders Are Scooping Up Shares of These 5 Stocks

Here's a technical look at how to trade five stocks that have seen recent insider buying.

The Medicines Company Announces Initiation Of Phase II Study For Its Investigational Anesthetic, ABP-700

The Medicines Company Announces Initiation Of Phase II Study For Its Investigational Anesthetic, ABP-700

The Medicines Company announced today that it has dosed the first patient in a Phase II study of ABP-700 in procedural sedation.

The Medicines Company Announces Participation At ASM MICROBE 2016 To Be Held June 16 - 20 In Boston

The Medicines Company Announces Participation At ASM MICROBE 2016 To Be Held June 16 - 20 In Boston

The Medicines Company (NASDAQ:MDCO) today announced that 11 presentations on its infectious disease programs will be presented at the first annual ASM Microbe 2016 to be held June 16-20 in Boston, MA.

MDCO: Insiders vs. Shorts

MDCO: Insiders vs. Shorts

The most recent short interest data was recently released for the 03/31/2016 settlement date, and Medicines Co is one of the most shorted stocks of the Russell 3000, based on 13.02 "days to cover" versus the median component at 5.75. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Medicines (MDCO) Moving On Heavy Pre-Market Trading

Medicines (MDCO) Moving On Heavy Pre-Market Trading

Trade-Ideas LLC identified Medicines (MDCO) as a pre-market mover with heavy volume candidate

The Medicines Company Prices $350 Million Of Convertible Notes

The Medicines Company Prices $350 Million Of Convertible Notes

The Medicines Company (NASDAQ:MDCO) (the "Company") today announced that it has priced its private offering of $350 million in aggregate principal amount of its convertible senior notes due 2023.

Barbarian At The Gate: Medicines (MDCO)

Barbarian At The Gate: Medicines (MDCO)

Trade-Ideas LLC identified Medicines (MDCO) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

The Medicines Company Announces Intention To Offer $350 Million Of Convertible Notes

The Medicines Company Announces Intention To Offer $350 Million Of Convertible Notes

The Medicines Company (NASDAQ:MDCO) (the "Company") today announced that it proposes to offer $350 million aggregate principal amount of convertible senior notes due 2023, subject to market conditions and other factors.

The Medicines Company Completes Patient Enrollment For ORION-1 Study Of PCSK9si

The Medicines Company Completes Patient Enrollment For ORION-1 Study Of PCSK9si

The Medicines Company (NASDAQ:MDCO) has announced the completion of patient enrollment in the ORION-1 study of PCSK9si, its investigational first-in-class RNA interference (RNAi) proprotein convertase subtilisin/kexin type...

The Medicines Company Announces Completion Of Patient Enrollment In Phase 3 TANGO 1 Study Of CARBAVANCE® (meropenem-vaborbactam) For Treatment Of Complicated Urinary Tract Infections (cUTI)

The Medicines Company Announces Completion Of Patient Enrollment In Phase 3 TANGO 1 Study Of CARBAVANCE® (meropenem-vaborbactam) For Treatment Of Complicated Urinary Tract Infections (cUTI)

The Medicines Company (NASDAQ:MDCO) has announced the completion of patient enrollment in the Phase 3 TANGO 1 study of CARBAVANCE® (meropenem-vaborbactam), an investigational agent being developed for the treatment of...

The Medicines Company To Present At Two Upcoming Investor Conferences

The Medicines Company To Present At Two Upcoming Investor Conferences

The Medicines Company (NASDAQ:MDCO) today announced that the company is scheduled to make presentations at the following June investor conferences: Jefferies 2016 Healthcare Conference - New York City, Tuesday,...

5 Stocks Insiders Are Scooping Up Right Now

5 Stocks Insiders Are Scooping Up Right Now

Insiders at these five companies have been buying shares of their own stock recently. Should you?

The Medicines Company Appoints Tony Kingsley As President And Chief Operating Officer

The Medicines Company Appoints Tony Kingsley As President And Chief Operating Officer

The Medicines Company (NASDAQ:MDCO) has announced the appointment of Tony Kingsley as President and Chief Operating Officer.

The Medicines Company Reports First-Quarter 2016 Business And Financial Results

The Medicines Company Reports First-Quarter 2016 Business And Financial Results

The Medicines Company (NASDAQ:MDCO) today announced its business and financial results for the first quarter ended March 31, 2016.

The Medicines Company Agrees To Divest Non-Core Cardiovascular Assets To Chiesi Farmaceutici S.p.A.

The Medicines Company Agrees To Divest Non-Core Cardiovascular Assets To Chiesi Farmaceutici S.p.A.

The Medicines Company (NASDAQ:MDCO) today announced that it has entered into a definitive agreement to sell Cleviprex® (clevidipine), Kengreal® (cangrelor) and the Company's rights to Argatroban for Injection to...

The Medicines Company To Present At Bank Of America Merrill Lynch 2016 Health Care Conference

The Medicines Company To Present At Bank Of America Merrill Lynch 2016 Health Care Conference

The Medicines Company (NASDAQ:MDCO) is scheduled to present at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas, NV on Tuesday, May 10, 2016, at 8:00 AM PT (11:00 AM ET).

The Medicines Company To Announce First Quarter Financial Results On May 9, 2016

The Medicines Company To Announce First Quarter Financial Results On May 9, 2016

The Medicines Company (NASDAQ:MDCO) has scheduled its quarterly conference call for May 9 th at 8:30 a.

TheStreet Quant Rating: D (Sell)